About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« One More on That Buckyball Longevity Paper | Main | The UK Goes Open-Access »

May 10, 2012

GSK Goes Hostile

Email This Entry

Posted by Derek

I mentioned the other day that Human Genome Sciences had turned down an offer from GSK, feeling that they could do better. Well, if they can, now's the time: GSK is now offering the same deal ($13/share) on the open market in a hostile takeover attempt. One of these companies is wrong about that price, and now I guess we'll find out which one of them it is. . .

Comments (7) + TrackBacks (0) | Category: Business and Markets


1. PharmaTwoPointZero on May 10, 2012 7:40 AM writes...

Derek, I think this deal will go through, Sir Andrew would not have shown his hand in this manner if he did not feel confident about succeeding, he's the sort of guy who knows what he want and knows how to get it. This also appears to be the final consummation of an already close relationship and is clearly as much in the interests of HGS as GSK. Sir Andrew has spoken many times of his disavowal of mega-mergers in favor of niche deals such as this one. Time will tell where the final price ends up but rest assured that the deal will materialize and will deliver drugs for patients. Watch this space!

Permalink to Comment

2. Calvin on May 10, 2012 9:25 AM writes...

Yay for Sir Andrew!!!! He's my hero.....

Permalink to Comment

3. Rev. Howard Furst on May 10, 2012 9:35 AM writes...

Do not mock Sir Andrew or his sycophants. He is the Chuck Norris of Pharma. Drugs run to discover him.

Permalink to Comment

4. Calvin on May 10, 2012 10:22 AM writes...

I do actually think Sir Andrew is pretty good. Fawning sycophants not so much

Permalink to Comment

5. Anonymous on May 10, 2012 11:06 AM writes...

Chuck Norris! LOL!

Permalink to Comment

6. doctorpat on May 20, 2012 10:19 PM writes...

One of these companies is wrong about that price,

Actually, both companies agree about the price.

HGS thinks that the price is low, which is why they don't want to sell.
And GSK ALSO thinks that the price is low, which is why they want to buy.

Permalink to Comment

7. Ksw 31 stream on April 23, 2015 10:59 AM writes...

Another advantage of reciprocal linking is that it you don't require to go to sites that are not relevant to you. You only link to the sites that provide similar services as yours. By establishing a relation with only relevant sites you can pull potential customers to your site and improve your rankings. This usually does not happen when you are linked to non-relevant sites. In case of reciprocal link building, you always have a reason to explain why you want to link to that particular site. You can also convince the webmaster of a particular site by emphasizing on the fact that reciprocal links will benefit both. Above all, the websites with which reciprocal links are established has a better page ranking that means they have more visitors than yours. So, it is likely that it will greatly help in driving traffic to your site.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry